Literature DB >> 15194763

Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins.

Mike Flint1, Carine Logvinoff, Charles M Rice, Jane A McKeating.   

Abstract

The recent development of infectious retroviral pseudotypes bearing hepatitis C virus (HCV) glycoproteins represents an opportunity to study the functionally active form of the HCV E1 and E2 glycoproteins. In the culture supernatant of cells producing HCV retroviral pseudotypes, the majority of E2 was not associated with infectious particles and failed to sediment on sucrose gradients. The E2 that was incorporated into infectious particles appeared as a triplet of diffuse bands at 60, 70, and 90 kDa. Similarly, three major forms of E1 were incorporated into the pseudotype particles, migrating at 33, 31, and 25 kDa. Endoglycosidase H (endo-H) treatment of particles demonstrated that the incorporated E1 was partially or completely sensitive to digestion. In contrast, the majority of the incorporated E2 was endo-H resistant. Purified pseudotype particles were found to contain both disulfide-linked aggregates and nonaggregated E1 and E2. HCV pseudotypes generated from cells expressing E1E2p7 showed similar heterogeneity in the incorporated glycoproteins and were of comparable infectivity to those generated by expression of E1E2. Our results demonstrate the heterogeneous nature of E1 and E2 incorporated into retroviral pseudotypes and highlight the difficulty in identifying forms of the HCV glycoproteins that initiate infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194763      PMCID: PMC421632          DOI: 10.1128/JVI.78.13.6875-6882.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein.

Authors:  M Ohuchi; A Cramer; M Vey; R Ohuchi; W Garten; H D Klenk
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

2.  Two hepatitis C virus glycoprotein E2 products with different C termini.

Authors:  H Mizushima; M Hijikata; S Asabe; M Hirota; K Kimura; K Shimotohno
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

3.  Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins.

Authors:  Heidi E Drummer; Anne Maerz; Pantelis Poumbourios
Journal:  FEBS Lett       Date:  2003-07-10       Impact factor: 4.124

4.  Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport.

Authors:  K Takeuchi; R A Lamb
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

5.  Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses.

Authors:  J Dubuisson; H H Hsu; R C Cheung; H B Greenberg; D G Russell; C M Rice
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences.

Authors:  Akito Sakai; Marisa St Claire; Kristina Faulk; Sugantha Govindarajan; Suzanne U Emerson; Robert H Purcell; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

7.  CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.

Authors:  Jie Zhang; Glenn Randall; Adrian Higginbottom; Peter Monk; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Uncleaved NS2-3 is required for production of infectious bovine viral diarrhea virus.

Authors:  Eugene V Agapov; Catherine L Murray; Ilya Frolov; Lin Qu; Tina M Myers; Charles M Rice
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini.

Authors:  C Lin; B D Lindenbach; B M Prágai; D W McCourt; C M Rice
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Expression of unmodified hepatitis C virus envelope glycoprotein-coding sequences leads to cryptic intron excision and cell surface expression of E1/E2 heterodimers comprising full-length and partially deleted E1.

Authors:  Julie Dumonceaux; Emmanuel G Cormier; Francis Kajumo; Gerald P Donovan; Jayanta Roy-Chowdhury; Ira J Fox; Jason P Gardner; Tatjana Dragic
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  38 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay.

Authors:  Mariko Kobayashi; Michael C Bennett; Theodore Bercot; Ila R Singh
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Authors:  Gopal Sapparapu; Stephanie A Planque; Yasuhiro Nishiyama; Steven K Foung; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

4.  The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain.

Authors:  César G Albariño; Brian H Bird; Ayan K Chakrabarti; Kimberly A Dodd; Mike Flint; Eric Bergeron; David M White; Stuart T Nichol
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

Review 5.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

6.  Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus.

Authors:  Ana Montero; Pablo Gastaminza; Mansun Law; Guofeng Cheng; Francis V Chisari; M Reza Ghadiri
Journal:  Chem Biol       Date:  2011-11-23

7.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Novel function of CD81 in controlling hepatitis C virus replication.

Authors:  Yong-Yuan Zhang; Bai-Hua Zhang; Koji Ishii; T Jake Liang
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

Review 9.  Hepatitis C Virus entry: the early steps in the viral replication cycle.

Authors:  Ali Sabahi
Journal:  Virol J       Date:  2009-07-30       Impact factor: 4.099

10.  Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry.

Authors:  Hsiao-Fen Li; Chia-Hsuan Huang; Li-Shuang Ai; Chin-Kai Chuang; Steve S L Chen
Journal:  J Biomed Sci       Date:  2009-09-24       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.